Pittenger & Anderson Inc. Has $26.81 Million Stock Holdings in ResMed Inc. $RMD

Pittenger & Anderson Inc. boosted its holdings in ResMed Inc. (NYSE:RMD) by 4.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 97,952 shares of the medical equipment provider’s stock after buying an additional 4,122 shares during the quarter. ResMed makes up 1.0% of Pittenger & Anderson Inc.’s holdings, making the stock its 24th biggest holding. Pittenger & Anderson Inc. owned approximately 0.07% of ResMed worth $26,812,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Entropy Technologies LP raised its stake in shares of ResMed by 188.7% during the second quarter. Entropy Technologies LP now owns 16,384 shares of the medical equipment provider’s stock valued at $4,227,000 after acquiring an additional 10,708 shares during the last quarter. Quantbot Technologies LP raised its position in ResMed by 244.8% during the 2nd quarter. Quantbot Technologies LP now owns 36,355 shares of the medical equipment provider’s stock worth $9,380,000 after purchasing an additional 25,810 shares during the last quarter. Nordea Investment Management AB lifted its holdings in ResMed by 3.5% during the 3rd quarter. Nordea Investment Management AB now owns 790,872 shares of the medical equipment provider’s stock worth $217,387,000 after buying an additional 26,629 shares during the period. American Century Companies Inc. increased its stake in shares of ResMed by 0.7% in the second quarter. American Century Companies Inc. now owns 175,901 shares of the medical equipment provider’s stock valued at $45,382,000 after buying an additional 1,183 shares during the period. Finally, Swedbank AB raised its position in shares of ResMed by 25.4% during the third quarter. Swedbank AB now owns 542,711 shares of the medical equipment provider’s stock worth $148,556,000 after acquiring an additional 109,760 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

More ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat expectations — EPS (non‑GAAP $2.81) topped estimates and revenue of $1.423B was ~11% year‑over‑year growth, driven by device and mask demand; investors are pricing in continued top‑line momentum. ResMed beats quarterly profit estimates on strong demand for its sleep devices
• Positive Sentiment: Margins and cash flow improved — GAAP gross margin rose ~320 bps to 61.8%, operating cash flow was ~$340M and non‑GAAP EPS grew mid‑teens, supporting profitability outlook. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Positive Sentiment: Shareholder returns raised — board declared a $0.60 quarterly cash dividend (payable March 19) and the company repurchased $175M of stock in the quarter, boosting capital return credibility. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Neutral Sentiment: Product & regulatory progress — received FDA clearance for an AI‑enabled comfort feature (Smart Comfort) that may aid adherence and product differentiation, but commercial impact will be gradual. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Neutral Sentiment: Investor sentiment / analyst context — multiple analysts maintain positive views and price targets remain well above current levels (median ~ $300), which supports upside but also sets expectations. Resmed Inc. Reports 11% Revenue Growth and Strong Margin Improvement in Q2 Fiscal Year 2026
• Negative Sentiment: Costs and one‑time items rose — SG&A and R&D grew (~12% yo‑y on a constant currency basis) and the company recorded ~$6M of restructuring charges; rising operating expenses could cap margin upside if growth slows. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Negative Sentiment: Insider selling activity noted — recent disclosures show multiple insider sales across senior executives over the past 6 months, which some investors view as a cautionary signal. Resmed Inc. Reports 11% Revenue Growth and Strong Margin Improvement in Q2 Fiscal Year 2026

Insiders Place Their Bets

In other ResMed news, Director Witte Jan De sold 2,055 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total value of $524,025.00. Following the completion of the transaction, the director owned 4,261 shares in the company, valued at approximately $1,086,555. This represents a 32.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael J. Farrell sold 8,011 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $249.75, for a total value of $2,000,747.25. Following the completion of the sale, the chief executive officer directly owned 467,866 shares in the company, valued at approximately $116,849,533.50. This represents a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 21,594 shares of company stock worth $5,403,495. 0.65% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. KeyCorp boosted their price target on shares of ResMed from $298.00 to $299.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Royal Bank Of Canada increased their price target on ResMed from $300.00 to $303.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Morgan Stanley set a $305.00 price objective on ResMed in a research note on Friday, October 31st. Stifel Nicolaus lowered their target price on ResMed from $270.00 to $260.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Finally, UBS Group reiterated a “buy” rating and set a $345.00 price objective on shares of ResMed in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, ResMed currently has a consensus rating of “Moderate Buy” and an average price target of $296.09.

ResMed Price Performance

ResMed stock opened at $257.83 on Friday. ResMed Inc. has a one year low of $199.92 and a one year high of $293.81. The business has a fifty day moving average price of $250.90 and a 200-day moving average price of $263.20. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.89 and a quick ratio of 2.13. The firm has a market capitalization of $37.63 billion, a P/E ratio of 26.39, a PEG ratio of 1.73 and a beta of 0.88.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. ResMed had a net margin of 27.35% and a return on equity of 25.45%. The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the business earned $2.43 EPS. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. As a group, equities research analysts forecast that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, February 12th. ResMed’s dividend payout ratio is 24.56%.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.